Re: Published Withdrawal Studies .... inc one by Kutcher

[Guest guest]

That "puke" as you call him Jim appears to have authored (one out of four) a paper that supports the position that SSRI's are indeed associated with a withdrawal syndrome. So does that make him a good guy .... or mixed good guy/bad guy.

Or is it a case that this is typical of the scientific process and all papers on the subject should be taken in the round.?

> >> >> > Selective serotonin reuptake inhibitor discontinuation syndrome: > > proposed diagnostic criteria.> > K Black, C Shea, S Dursun, and S Kutcher> > Department of Psychiatry, Dalhousie University, Halifax, NS.> > http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1407715/> > Small right arrow pointing to: See letter "Selective serotonin > > reuptake inhibitors and discontinuation symptoms. > > </pmc/articles/PMC1407747/>" in volume 26 on page 152a.> > Small right arrow pointing to: This article has been cited by > > </pmc/articles/PMC1407715/citedby/> other articles in PMC.> > Abstract> > OBJECTIVE: To establish specific criteria by which selective serotonin > > reuptake inhibitor (SSRI) discontinuation syndrome may be identified. > > DATA SOURCES: MEDLINE and PSYCHLIT databases were searched for case > > reports published from 1986 to 1997 inclusive, and references of > > relevant articles were also searched. STUDY SELECTION: Forty-six case > > reports of symptoms following the discontinuation of fluoxetine, > > fluvoxamine, paroxetine or sertraline were selected. Three studies of > > SSRI discontinuation were also reviewed. DATA EXTRACTION: Demographic > > and treatment information, as well as the timing, duration, number, > > nature and frequency of dicontinuation symptoms. DATA SYNTHESIS: > > Paroxetine was most frequently implicated. The drug had been tapered > > in half of the cases. In some cases, symptom onset began during taper, > > whereas, in most cases, symptoms began within 1 to 3 days of drug > > discontinuation. Fifty-three different symptoms were reported, with > > dizziness being the most common. Other common symptoms were nausea or > > emesis, fatigue, headache, gait instability and insomnia. Shock-like > > sensations, paresthesia and visual disturbances were the most rare. > > Without intervention, symptoms persisted for more than a week in half > > of the cases. In cases in which the SSRI was restarted, symptoms > > resolved within 72 hours. In some cases, withdrawal symptoms recurred > > when the same SSRI was again discontinued. CONCLUSIONS: Findings were > > used to construct diagnostic criteria for the SSRI discontinuation > > syndrome. These criteria are 2 or more of the following symptoms > > developing within 1 to 7 days of discontinuation or reduction in > > dosage of an SSRI after at least 1 month's use, when these symptoms > > cause clinically significant distress or impairment and are not due to > > a general medical condition or recurrence of a mental disorder: > > dizziness, light-headedness, vertigo or feeling faint; shock-like > > sensations or paresthesia; anxiety; diarrhea; fatigue; gait > > instability; headache; insomnia; irri! tability; nausea or emesis; > > tremor; and visual disturbances.> > Full text> > Full text is available as a scanned copy of the original print > > version. Get a printable copy (PDF file) of the *complete article* > > </pmc/articles/PMC1407715/pdf/jpn00086-0041.pdf> (1.7M), or click on a > > page image below to browse page by page. Links to PubMed are also > > available for *Selected References* > > </pmc/articles/PMC1407715/#reference-sec>.> > icon of scanned page 255> > 255> > </pmc/articles/PMC1407715/?page=1>> > icon of scanned page 256> > 256> > </pmc/articles/PMC1407715/?page=2>> > icon of scanned page 257> > 257> > </pmc/articles/PMC1407715/?page=3>> > icon of scanned page 258> > 258> > </pmc/articles/PMC1407715/?page=4>> > icon of scanned page 259> > 259> > </pmc/articles/PMC1407715/?page=5>> > icon of scanned page 260> > 260> > </pmc/articles/PMC1407715/?page=6>> > icon of scanned page 261> > 261> > </pmc/articles/PMC1407715/?page=7>> >> >> >>

[Guest guest]

He's a puke to me. Period. Buzzard puke to be exact.

Stating the obvious on the AD withdrawal does not make him a good

guy.

Being involved with a twisted study that harmed children by

promoting Paxil makes him a very bad guy.

On 5/1/2011 4:26 PM, jeremy9282 wrote:

That "puke" as you call him Jim appears to have authored (one

out of four) a paper that supports the position that SSRI's are

indeed associated with a withdrawal syndrome. So does that make

him a good guy .... or mixed good guy/bad guy.

Or is it a case that this is typical of the scientific process

and all papers on the subject should be taken in the round.?

> >

> >

> > Selective

serotonin reuptake inhibitor discontinuation syndrome:

> > proposed diagnostic criteria.

> > K Black, C Shea, S Dursun, and S Kutcher

> > Department of Psychiatry, Dalhousie University,

Halifax, NS.

> > http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1407715/

> > Small right arrow pointing to: See letter "Selective

serotonin

> > reuptake inhibitors and discontinuation

symptoms.

> > </pmc/articles/PMC1407747/>" in volume 26 on

page 152a.

> > Small right arrow pointing to: This article has been

cited by

> > </pmc/articles/PMC1407715/citedby/> other

articles in PMC.

> > Abstract

> > OBJECTIVE: To establish specific criteria by which

selective serotonin

> > reuptake inhibitor (SSRI) discontinuation syndrome may

be identified.

> > DATA SOURCES: MEDLINE and PSYCHLIT databases were

searched for case

> > reports published from 1986 to 1997 inclusive, and

references of

> > relevant articles were also searched. STUDY SELECTION:

Forty-six case

> > reports of symptoms following the discontinuation of

fluoxetine,

> > fluvoxamine, paroxetine or sertraline were selected.

Three studies of

> > SSRI discontinuation were also reviewed. DATA

EXTRACTION: Demographic

> > and treatment information, as well as the timing,

duration, number,

> > nature and frequency of dicontinuation symptoms. DATA

SYNTHESIS:

> > Paroxetine was most frequently implicated. The drug

had been tapered

> > in half of the cases. In some cases, symptom onset

began during taper,

> > whereas, in most cases, symptoms began within 1 to 3!

days of drug

> > discontinuation. Fifty-three different symptoms were

reported, with

> > dizziness being the most common. Other common symptoms

were nausea or

> > emesis, fatigue, headache, gait instability and

insomnia. Shock-like

> > sensations, paresthesia and visual disturbances were

the most rare.

> > Without intervention, symptoms persisted for more than

a week in half

> > of the cases. In cases in which the SSRI was

restarted, symptoms

> > resolved within 72 hours. In some cases, withdrawal

symptoms recurred

> > when the same SSRI was again discontinued.

CONCLUSIONS: Findings were

> > used to construct diagnostic criteria for the SSRI

discontinuation

> > syndrome. These criteria are 2 or more of the

following symptoms

> > developing within 1 to 7 days of discontinuation or

reduction in

> > dosage of an SSRI after at least 1 month's use, when

these symptoms

> > cause clinically significant distress or impairment

and are not due to

> > a general medical condition or recurrence of a mental

disorder:

> > dizziness, light-headedness, vertigo or feeling faint;

shock-like

> > sensations or paresthesia; anxiety; diarrhea; fatigue;

gait

> > instability; headache; insomnia; irri! tability;

nausea or emesis;

> > tremor; and visual disturbances.

> > Full text

> > Full text is available as a scanned copy of the

original print

> > version. Get a printable copy (PDF file) of the

*complete article*

> > </pmc/articles/PMC1407715/pdf/jpn00086-0041.pdf>

(1.7M), or click on a

> > page image below to browse page by page. Links to

PubMed are also

> > available for *Selected References*

> > </pmc/articles/PMC1407715/#reference-sec>.

> > icon of scanned page 255

> > 255

> > </pmc/articles/PMC1407715/?page=1>

> > icon of scanned pag! e 256

> > 256

> > </pmc/articles/PMC1407715/?page=2>

> > icon of scanned page 257

> > 257

> > </pmc/articles/PMC1407715/?page=3>

> > icon of scanned page 258

> > 258

> > </pmc/articles/PMC1407715/?page=4>

> > icon of scanned page 259

> > 259

> > </pmc/articles/PMC1407715/?page=5>

> > icon of scanned page 260

> > 260

> > </pmc/articles/PMC1407715/?page=6>

> > icon of scanned page 261

> > 261

> > </pmc/articles/PMC1407715/?page=7>

> >

> >

> >

>

[Guest guest]

,

We know Texas psychiatrist D. Wagner was part of that same

study and was found to have been paid 160,000 dollars, if I

remember the amount correctly, undisclosed. Still working, still

writing studies, not in jail.

Kutcher is Canadian and as far as I know hasn't been investigated

like Wagner and some others were. Which is a shame.

I'm off for now.

Cheers,

Jim

On 5/1/2011 4:26 PM, jeremy9282 wrote:

That "puke" as you call him Jim appears to have authored (one

out of four) a paper that supports the position that SSRI's are

indeed associated with a withdrawal syndrome. So does that make

him a good guy .... or mixed good guy/bad guy.

Or is it a case that this is typical of the scientific process

and all papers on the subject should be taken in the round.?

> >

> >

> > Selective

serotonin reuptake inhibitor discontinuation syndrome:

> > proposed diagnostic criteria.

> > K Black, C Shea, S Dursun, and S Kutcher

> > Department of Psychiatry, Dalhousie University,

Halifax, NS.

> > http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1407715/

> > Small right arrow pointing to: See letter "Selective

serotonin

> > reuptake inhibitors and discontinuation

symptoms.

> > </pmc/articles/PMC1407747/>" in volume 26 on

page 152a.

> > Small right arrow pointing to: This article has been

cited by

> > </pmc/articles/PMC1407715/citedby/> other

articles in PMC.

> > Abstract

> > OBJECTIVE: To establish specific criteria by which

selective serotonin

> > reuptake inhibitor (SSRI) discontinuation syndrome may

be identified.

> > DATA SOURCES: MEDLINE and PSYCHLIT databases were

searched for case

> > reports published from 1986 to 1997 inclusive, and

references of

> > relevant articles were also searched. STUDY SELECTION:

Forty-six case

> > reports of symptoms following the discontinuation of

fluoxetine,

> > fluvoxamine, paroxetine or sertraline were selected.

Three studies of

> > SSRI discontinuation were also reviewed. DATA

EXTRACTION: Demographic

> > and treatment information, as well as the timing,

duration, number,

> > nature and frequency of dicontinuation symptoms. DATA

SYNTHESIS:

> > Paroxetine was most frequently implicated. The drug

had been tapered

> > in half of the cases. In some cases, symptom onset

began during taper,

> > whereas, in most cases, symptoms began within 1 to 3!

days of drug

> > discontinuation. Fifty-three different symptoms were

reported, with

> > dizziness being the most common. Other common symptoms

were nausea or

> > emesis, fatigue, headache, gait instability and

insomnia. Shock-like

> > sensations, paresthesia and visual disturbances were

the most rare.

> > Without intervention, symptoms persisted for more than

a week in half

> > of the cases. In cases in which the SSRI was

restarted, symptoms

> > resolved within 72 hours. In some cases, withdrawal

symptoms recurred

> > when the same SSRI was again discontinued.

CONCLUSIONS: Findings were

> > used to construct diagnostic criteria for the SSRI

discontinuation

> > syndrome. These criteria are 2 or more of the

following symptoms

> > developing within 1 to 7 days of discontinuation or

reduction in

> > dosage of an SSRI after at least 1 month's use, when

these symptoms

> > cause clinically significant distress or impairment

and are not due to

> > a general medical condition or recurrence of a mental

disorder:

> > dizziness, light-headedness, vertigo or feeling faint;

shock-like

> > sensations or paresthesia; anxiety; diarrhea; fatigue;

gait

> > instability; headache; insomnia; irri! tability;

nausea or emesis;

> > tremor; and visual disturbances.

> > Full text

> > Full text is available as a scanned copy of the

original print

> > version. Get a printable copy (PDF file) of the

*complete article*

> > </pmc/articles/PMC1407715/pdf/jpn00086-0041.pdf>

(1.7M), or click on a

> > page image below to browse page by page. Links to

PubMed are also

> > available for *Selected References*

> > </pmc/articles/PMC1407715/#reference-sec>.

> > icon of scanned page 255

> > 255

> > </pmc/articles/PMC1407715/?page=1>

> > icon of scanned pag! e 256

> > 256

> > </pmc/articles/PMC1407715/?page=2>

> > icon of scanned page 257

> > 257

> > </pmc/articles/PMC1407715/?page=3>

> > icon of scanned page 258

> > 258

> > </pmc/articles/PMC1407715/?page=4>

> > icon of scanned page 259

> > 259

> > </pmc/articles/PMC1407715/?page=5>

> > icon of scanned page 260

> > 260

> > </pmc/articles/PMC1407715/?page=6>

> > icon of scanned page 261

> > 261

> > </pmc/articles/PMC1407715/?page=7>

> >

> >

> >

>

[Guest guest]

Yes Jim it seems the longer the treatment lasts the worse most become

.....it's all very sad.

> > > > > >

> > > > > >

> > > > > > Selective serotonin reuptake inhibitor discontinuation

syndrome:

> > > > > > proposed diagnostic criteria.

> > > > > > K Black, C Shea, S Dursun, and S Kutcher

> > > > > > Department of Psychiatry, Dalhousie University, Halifax, NS.

> > > > > > http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1407715/

> > > > > > Small right arrow pointing to: See letter " Selective

serotonin

> > > > > > reuptake inhibitors and discontinuation symptoms.

> > > > > > </pmc/articles/PMC14077! 47/> " in volume 26 on page 152a.

> > > > > > Small right arrow pointing to: This article has been cited

by

> > > > > > </pmc/articles/PMC1407715/citedby/> other articles in PMC.

> > > > > > Abstract

> > > > > > OBJECTIVE: To establish specific criteria by which selective

> > > > serotonin

> > > > > > reuptake inhibitor (SSRI) discontinuation syndrome may be

> > identified.

> > > > > > DATA SOURCES: MEDLINE and PSYCHLIT databases were searched

for

> > case

> > > > > > reports published from 1986 to 1997 inclusive, and

references of

> > > > > > relevant articles were also searched. STUDY SELECTION:

> > Forty-six case

> > > > > > reports of symptoms following the discontinuation of

fluoxetine,

> > > > > > fluvoxamine, paroxetine or sertraline were selected. Three

> > studies of

> > > > > > SSRI discontinuation were also reviewed. DATA EXTRACTION:

> > Demographic

> > > > > > and treatment information, as well as the timing, duration,

> > number,

> > > > > > nature and frequency of dicontinuation symptoms. DATA

SYNTHESIS:

> > > > > > Paroxetine was most frequently implicated. The drug had been

> > tapered

> > > > > > in half of the cases. In some cases, symptom onset began

during

> > > > taper,

> > > > > > whereas, in most cases, symptoms began within 1 to 3! days

of drug

> > > > > > discontinuation. Fifty-three different symptoms were

reported,

> > with

> > > > > > dizziness being the most common. Other common symptoms were

> > nausea or

> > > > > > emesis, fatigue, headache, gait instability and insomnia.

> > Shock-like

> > > > > > sensations, paresthesia and visual disturbances were the

most

> > rare.

> > > > > > Without intervention, symptoms persisted for more than a

week

> > in half

> > > > > > of the cases. In cases in which the SSRI was restarted,

symptoms

> > > > > > resolved within 72 ! hours. In some cases, withdrawal

symptoms

> > recurred

> > > > > > when the same SSRI was again discontinued. CONCLUSIONS:

> > Findings were

> > > > > > used to construct diagnostic criteria for the SSRI

discontinuation

> > > > > > syndrome. These criteria are 2 or more of the following

symptoms

> > > > > > developing within 1 to 7 days of discontinuation or

reduction in

> > > > > > dosage of an SSRI after at least 1 month's use, when these

> > symptoms

> > > > > > cause clinically significant distress or impairment and are

not

> > > > due to

> > > > > > a general medical condition or recurrence of a mental

disorder:

> > > > > > dizziness, light-headedness, vertigo or feeling faint;

shock-like

> > > > > > sensations or paresthesia; anxiety; diarrhea; fatigue; gait

> > > > > > instability; headache; insomnia; irri! tability; nausea or

emesis;

> > > > > > tremor; and visual disturbances.

> > > > > > Full text

> > > > > > Full text is available as a scanned copy of the original

print

> > > > > > version. Get a printable copy (PDF file) of the *complete

article*

> > > > > > </pmc/articles/PMC1407715/pdf/jpn00086-0041.pdf> (1.7M), or

click

> > > > on a

> > > > > > page image below to browse page by page. Links to PubMed are

also

> > > > > > available for *Selected References*

> > > > > > </pmc/articles/PMC1407715/#reference-sec>.

> > > > > > icon of scanned page 255

> > > > > > 255

> > > > > > </pmc/articles/PMC1407715/?page=1>

> > > > > > icon of scanned pag! e 256

> > > > > > 256

> > > > > > </pmc/articles/PMC1407715/?page=2>

> > > > > > icon of scanned page 257

> > > > > > 257

> > > > > > </pmc/articles/PMC1407715/?page=3>

> > > > > > icon of scanned page 258

> > > > > > ! 258

> > > > > > </pmc/articles/PMC1407715/?page=4>

> > > > > > icon of scanned page 259

> > > > > > 259

> > > > > > </pmc/articles/PMC1407715/?page=5>

> > > > > > icon of scanned page 260

> > > > > > 260

> > > > > > </pmc/articles/PMC1407715/?page=6>

> > > > > > icon of scanned page 261

> > > > > > 261

> > > > > > </pmc/articles/PMC1407715/?page=7>

> > > > > >

> > > > > >

> > > > > >

> > > > >

> > > >

> > > >

> > > >

> > > >

> > >

> >

> >

> >

> >

>